U.S. Zymergen completes 440 million Series C funding

U.S.-based molecular technology startup Zymergen has completed $400 million in Series C funding.

The investments came from SoftBank Vision Fund, the investment firm of Japanese technology to telecommunications company SoftBank.

Additionally, new backers including U.S.-based investment bank Goldman Sachs and Hanwha Asset Management, as well as returning investors, Data Collective, True Ventures, Two Sigma Ventures, DFJ and Innovation Endeavors also participated the round.

With the capital raised, Zymergen will accelerate its growth through doubling the capacity of its platform to reach customer needs and also enhance its platform, increasing the speed and predictability with which it can program and optimize biology for specific traits.